CD300c Antibody (2799A) [Unconjugated]

MAB1050) followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse anti-Human CD14 Phycoerythrin-conjugated Monoclonal Antibody (FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." > MAB1050) followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse anti-Human CD14 Phycoerythrin-conjugated Monoclonal Antibody (FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." title="Human PBMC were stained with (A) Rabbit Anti-Human CD300c Monoclonal Antibody (Catalog # MAB3256) or (B) Rabbit IgG Isotype Control Antibody (MAB1050) followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse anti-Human CD14 Phycoerythrin-conjugated Monoclonal Antibody (FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." />

Human PBMC were stained with (A) Rabbit Anti-Human CD300c Monoclonal Antibody (Catalog # MAB3256) or (B) Rabbit IgG Isotype Control Antibody (<a class=

• Applications: Flow
• Clone: 2799A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

CD300c Antibody (2799A) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: NS0-derived human CD300c protein
  Met29-Arg183
  Accession # Q08708
• Specificity: Detects recombinant human CD300c in direct ELISA. In direct ELISAs, no cross-reactivity with Human CD300a, CD300e, CD300LG and Mouse CD300c was detected
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.5 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD300c Antibody (2799A) [Unconjugated]

• CD300c antigenCMRF35 antigen
• CD300c molecule
• CD300c
• CLM6
• CLM-6
• CMRF35 leukocyte immunoglobulin-like receptor
• CMRF35
• CMRF-35
• CMRF35A leukocyte immunoglobulin-like receptor
• CMRF-35A
• CMRF35ACMRF35A1
• CMRF35CMRF35-A1
• CMRF35-like molecule 6
• IGSF16
• IgSF16
• IGSF16CD300 antigen-like family member C
• Immunoglobulin superfamily member 16
• LIR

Background

Leukocyte mono-Ig-like receptor 2 (LMIR2; also CMRF-35, CMRF35-A antigen, and CD300c antigen) is a 23 kDa (predicted) type I transmembrane glycoprotein that belongs to the immunoregulatory signaling (IRS) family of molecules within the immunoglobulin (Ig) superfamily (1-4). Human LMIR2 is synthesized as a 224 amino acid (aa) precursor that has a 20 aa signal sequence, a 163 aa extracellular domain (ECD), a 21 aa transmembrane region, and a 20 aa cytoplasmic tail (SwissProt # Q08708). The ECD contains an Ig-like V-type domain (aa’s 22-128) and two N-linked glycosylation sites (aa’s 90 and 99). Downstream of the Ig V-domain, the membrane proximal region of LMIR2 (aa 128-183) contains a high proportion of proline (18%), serine (20%) and threonine (13%) residues (1). The transmembrane segment contains a charged glutamic acid that contributes to cell activation (1-3). Human LMIR2 shares 52% aa sequence identity with the mouse LMIR2, which is also known as CLM4. Human LMIR2 is 90% identical to human LMIR1 within the Ig-like domain. LMIR2 is present on the surface of natural killer cells, granulocytes, most myeloid cells, dendritic cells, and a subpopulation of T and B lymphocytes (1, 3). Mouse LMIR2 has the characteristics of an activatory molecule capable of inducing cellular activation and effector function in most cells and macrophages (3). The ligand for LMIR2 is presently unknown.

1. Jackson, D.G. et al. (1992) Eur. J. Immunol. 22:1157.
2. Clark, G.J. et al. (2001) Tissue Antigens 57:415.
3. Clark, G.J. et al. (2002) J. Biol. Regul. Homeost. Agents 16:233.
4. Daish, A. et al. (1993) Immunology 79:55.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for CD300c Antibody (MAB3256). (Showing 1 - 1 of 1 FAQ).

1. Why are there different molecular weight bands in western blot images for two of your antibodies (NBP1-84432 and H00010871-B01P) and overexpression lysate NBL1-08931?
   • A variety of band patterns can be expected when detecting CD300C. This protein has multiple glycosliation post-translational modifications that will change its molecular weight, and which vary in different experimental conditions. If you look at the uniprot link listed below, you can view more information on the specific PTMs for CD300C:https://www.uniprot.org/uniprot/Q08708#sequencesWe can be assured that these varying band patterns are indeed detection of CD300C by the absence of bands in the negative control. Any non-specific binding would show in both the negative and positive control, which is not the case here.

Bioinformatics

• Uniprot:
  • Q08708()